<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01461980</url>
  </required_header>
  <id_info>
    <org_study_id>B1971015</org_study_id>
    <secondary_id>6108A1-2005</secondary_id>
    <nct_id>NCT01461980</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age</brief_title>
  <official_title>A Phase 2, Randomized, Active-controlled, Observer-blinded Trial, To Assess The Safety, Tolerability, And Immunogenicity Of Mcv4, Tdap Vaccine And Bivalent Rlp2086 Vaccine When Administered Concomitantly In Healthy Subjects Aged &gt; = 10 To &lt;13 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical study to assess the safety, tolerance and immunogenic response to
      MCV4(quadrivalent meningococcal polysaccharide conjugate, meningococcal serogroups A,C,Y, and
      W135), Tdap (diphtheria, tetanus, and acellular pertussis), and bivalent rLP2086 vaccine.
      Healthy male and female subjects, between the ages of 10 to 12 years old, will be randomized
      into 1 of 3 groups. The subjects, investigators, site staff and sponsor will be blinded to
      all injections given throughout the study. An unblinded administrator will be responsible to
      administer the vaccinations to all subjects and will be unblinded to the subject
      randomization in order to determine which subjects were in randomized to group 3 so they may
      receive their catch-up vaccinations of MCV4 and Tdap. A final telephone contact will be
      conducted with all subjects 6-months post their last vaccination to obtain safety
      information.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Concentrations (GMC) for Diphtheria and Tetanus Antigens</measure>
    <time_frame>1 Month after Vaccination 1</time_frame>
    <description>Antibody GMCs of 2 antigens of diphtheria and tetanus toxoid were computed in International Units per milliliter (IU/mL) along with corresponding 2-sided 95 percent (%) confidence intervals (CIs). Here, 'number of participants analyzed' signifies participants with valid and determinate assay results for given antigen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentrations (GMC) for Acellular Pertussis Antigens</measure>
    <time_frame>1 Month after Vaccination 1</time_frame>
    <description>Antibody GMCs of 4 acellular pertussis antigens (pertussis toxoid, pertussis filamentous hemagglutinin, pertussis pertactin and pertussis fimbrial agglutinogens types 2+3) were computed in Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EU/mL) along with corresponding 2-sided 95% CIs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titer (GMT) for Meningococcal Conjugate Vaccine (MCV4) Antigens</measure>
    <time_frame>1 Month after Vaccination 1</time_frame>
    <description>Antibody GMTs of 4 MCV4 antigens (serogroup A, serogroup C, serogroup Y and serogroup W-135) were computed along with corresponding 2-sided 95% CIs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Bactericidal Assay Using Human Complement (hSBA) GMTs of PMB80 [A22] and PMB2948 [B24] 1 Month After Vaccination 3</measure>
    <time_frame>1 Month after Vaccination 3</time_frame>
    <description>Antibody hSBA GMTs of primary strain PMB80 [A22] and PMB2948 [B24] were computed along with corresponding 2-sided 95% CIs. hSBA titers from the 2 primary strains were logarithmically transformed for analysis. Here, 'number of participants analyzed' signifies evaluable immunogenicity population and 'N' signifies participants with valid and determinate assay results for given strain for each group, respectively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroresponse for Tetanus, Diphtheria and Acellular Pertussis (Tdap) and Meningococcal Conjugate Vaccine (MCV4) Antigens</measure>
    <time_frame>1 Month after Vaccination 1</time_frame>
    <description>Seroconversion rate for Tdap antigens was defined as greater than or equal to (&gt;=) 4-, 2-fold rise in antibody concentration, if prevaccination antibody concentration was less than or equal to (&lt;=), greater than (&gt;) cutoff value, respectively. For MCV4 antigens &gt;=4-fold rise on serum bactericidal assay using rabbit complement (rSBA) titers if baseline value &gt;= lower limit of quantitation (LLOQ), postdose rSBA titers &gt;=2Ã—LLOQ if baseline value was less than (&lt;) LLOQ. Cutoff value =0.1 IU/mL for diphtheria and tetanus, 0.9,2.9,3.0,10.6 EU/mL for pertussis toxoid, filamentous hemagglutinin, pertactin, fimbriae agglutinogens types 2 + 3, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Predefined Antibody Level for Diphtheria and Tetanus Antigens</measure>
    <time_frame>1 Month after Vaccination 1</time_frame>
    <description>Participants with antibody concentration level of greater than or equal to 1.0 IU/mL for diphtheria and tetanus antigens were computed along with corresponding 2-sided 95% CIs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Bactericidal Assay Using Human Complement (hSBA) GMTs of PMB80 [A22] and PMB2948 [B24] Before Vaccination 1 and 1 Month After Vaccination 2</measure>
    <time_frame>Before Vaccination 1, 1 Month after Vaccination (Vac) 2</time_frame>
    <description>Antibody hSBA of primary strain PMB80 [A22] and PMB2948 [B24] were computed along with corresponding 2-sided 95% CIs. hSBA titers from the 2 primary strains were logarithmically transformed for analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer &gt;= Lower Limit of Quantitation (LLOQ)</measure>
    <time_frame>Before Vaccination 1, 1 Month after Vaccination (Vac) 2, 3</time_frame>
    <description>Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95% CIs. LLOQ was 1:16 for PMB80 [A22] and 1:8 for PMB2948 [B24].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer &gt;= Prespecified Titer Level</measure>
    <time_frame>Before Vaccination 1, 1 Month after Vaccination (Vac) 2, 3</time_frame>
    <description>Antibody hSBA of primary strain PMB80 [A22] and PMB2948 [B24] with hSBA titers &gt;=1:4, &gt;=1:8, &gt;=1:16, &gt;=1:32, &gt;=1:64, and &gt;=1:128 were computed along with corresponding 2-sided 95% CIs.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Immunogloblulin G (IgG) Measured by GMC</measure>
    <time_frame>Before Vaccination 1, 1 Month after Vaccination 1</time_frame>
    <description>IgG GMCs of 4 MCV4 antigens (serogroup A, serogroup C, serogroup Y and serogroup W-135) of participants were computed along with corresponding 2-sided 95% CIs. CIs were back transformations of confidence levels based on Student t distribution for mean logarithm of titers.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants Achieving at Least 4-Fold Increase in Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level</measure>
    <time_frame>1 Month after Vaccination (Vac) 2, 3</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants With at Least One Adverse Event (AE)</measure>
    <time_frame>Vaccination phase (baseline up to 1 month after Vaccination 3); Follow-up phase (from 1 month up to 6 months after Vaccination 3)</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2648</enrollment>
  <condition>Vaccines</condition>
  <condition>Meningococcal Vaccines</condition>
  <arm_group>
    <arm_group_label>MCV4 + Tdap+ rLP2086</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 1 - MCV4 + Tdap + rLP2086</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MCV4 + Tdap + saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 2, MCV4 + Tdap+ saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline + saline + rLP2086</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group 3- rLP2086 + saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rLP2086 + MCV4 + Tdap</intervention_name>
    <description>At visit 1, group 1 will receive MCV4 + Tdap vaccines concomitantly with an injection of rLP2086. At visits 3 and 5 (Months 2 and 6), group 1 will receive an injection of rLP2086.</description>
    <arm_group_label>MCV4 + Tdap+ rLP2086</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MCV4 + Tdap + saline</intervention_name>
    <description>At visit 1, group 2 will receive MCV4 + Tdap vaccines concomitantly with an injection of saline. At visits 3 and 5 (months 2 and 6), this group will receive a saline injection only.</description>
    <arm_group_label>MCV4 + Tdap + saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rLP2086 + saline</intervention_name>
    <description>At visit 1, group 3 will receive 2 injections of saline concomitantly with an injection of rLP2086. At visits 3 and 5 (Months 2 and 6), group 3 will receive an injection of rLP2086. Subjects randomized to this group will receive MCV4 and Tdap following their final visit blood draw (Visit 6).</description>
    <arm_group_label>Saline + saline + rLP2086</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Evidence of a personally signed and dated informed consent document (ICD) indicating
             that the subject (and a legally authorized representative) has been informed of all
             pertinent aspects of the study.

          -  Parent /legally authorized representative and subjects who are willing and able to
             comply with scheduled visits, laboratory tests, and other study procedures.

          -  Male or female subject aged greater than or equal to 10 and &lt;13 years at the time of
             enrollment.

          -  Available for the entire study period and can be reached by telephone.

          -  Healthy subject as determined by medical history, physical examination, and judgment
             of the investigator.

          -  Has received full series (5-dose series is preferred, 4-dose catch up series is
             allowed) of diphtheria, tetanus and pertussis (whole cell or acellular) vaccines per
             country specific recommendations applicable at the time of receipt.

          -  Male and female subjects of childbearing potential must agree to use a highly
             effective method of contraception throughout the study.

        Exclusion Criteria:

          -  Previous vaccination with any meningococcal serogroup B vaccine.

          -  Vaccination with any diphtheria, tetanus or pertussis vaccine within 5 years of the
             first study vaccination.

          -  Previous vaccination with any MCV4 vaccine.

          -  A previous anaphylactic reaction to any vaccine or vaccine-related component.

          -  Contraindication to vaccination with MCV4 and/or Tdap vaccine.

          -  Subjects receiving any allergen immunotherapy with a non-licensed product or receiving
             allergen immunotherapy with a licensed product and are not on stable maintenance
             doses.

          -  Bleeding diathesis or condition associated with prolonged bleeding time that would
             contraindicate intramuscular injection.

          -  A known or suspected defect of the immune system that would prevent an immune response
             to the vaccine, such as subjects with congenital or acquired defects in B cell
             function, those receiving chronic systemic (oral, intravenous or intramuscular)
             corticosteroid therapy, or those receiving immunosuppressive therapy. Subjects with
             terminal complement deficiency may not be included.

          -  History of culture-proven disease caused by Neisseria meningitidis or Neisseria
             gonorrhoea.

          -  Significant neurological disorder or history of seizure (excluding simple febrile
             seizure).

          -  Receipt of any blood products, including immunoglobulin within 6 months before the
             first study vaccination.

          -  Current chronic use of systemic antibiotics.

          -  Any neuroinflammatory or autoimmune condition, including, but not limited to,
             transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Costal Clinical Research, Inc.</name>
      <address>
        <city>Daphne</city>
        <state>Alabama</state>
        <zip>36526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage Inc/ East Valley Family Physicians, PLC</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc./Mesa Family Medical Center, PC</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc./Desert</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Clinic of Jonesboro, PA</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Pediatric Clinic</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Fresno</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93726</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Hayward</name>
      <address>
        <city>Hayward</city>
        <state>California</state>
        <zip>94545</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Care Medical Group</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Health Care Pediatric Clinic</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Health Care - Moreno Valley Pediatrics</name>
      <address>
        <city>Moreno Valley</city>
        <state>California</state>
        <zip>92557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bayview Research Group, LLC</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Trials, LLC</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Sacramento</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Research Foundation</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bayview Research Group, LLC</name>
      <address>
        <city>Valley Village</city>
        <state>California</state>
        <zip>91607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Institute of the Rockies</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Springs Family Practice</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norwich Pediatric Group, P.C.</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine Department of Pediatrics</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Georgia Clinical Research Center dba Whites Pediatrics</name>
      <address>
        <city>Dalton</city>
        <state>Georgia</state>
        <zip>30721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatrics and Adolescent Medicine, PA</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatrics and Adolescent Medicine</name>
      <address>
        <city>Woodstock</city>
        <state>Georgia</state>
        <zip>30189</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Illinois Research Associates</name>
      <address>
        <city>DeKalb</city>
        <state>Illinois</state>
        <zip>60115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc./ Ridge Family Practice, PC</name>
      <address>
        <city>Council Bluffs</city>
        <state>Iowa</state>
        <zip>51503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Augusta</city>
        <state>Kansas</state>
        <zip>67010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Via Christi Clinic, P.A.</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Pediatric/Adult Research</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville Pediatrics: Children and Youth Project</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brownsboro Park Pediatrics</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bluegrass Clinical Research, Inc.</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40291</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwestern Medical Clinic Lakeland Healthcare Affiliate</name>
      <address>
        <city>Stevensville</city>
        <state>Michigan</state>
        <zip>49127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aspen Medical Group/ Odyssey Research</name>
      <address>
        <city>Saint Pail</city>
        <state>Minnesota</state>
        <zip>55108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aspen Medical Group</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allina Health Bandana Square Clinic</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Pharmaceutical Research, PC</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Health Research</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sundance Clinical Research, LLC</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage, Inc. / Prairie Fields Family Medicine, PC</name>
      <address>
        <city>Fremont</city>
        <state>Nebraska</state>
        <zip>68025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Children's Health Research Institute</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Clinical Research, Inc.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Creighton Pediatric Infectious Diseases Creighton University Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Nevada</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Child Health Care Associates</name>
      <address>
        <city>East Syracuse</city>
        <state>New York</state>
        <zip>13057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center - Duke Health Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durham Pediatrics</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Health Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Raleigh, LLC -</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Raleigh, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Raleigh, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovis Health</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odyssey Research</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Center for Clinical Research, Satellite Site - Clinic</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Childrens Hospital Medical Center Gamble Program for Clinical Studies</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Shelly David Senders, MD Inc. dba Senders Pediatrics</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Senders Pediatrics</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid Medical Research, Inc.</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio Pediatric Research Association</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio Pediatrics, Inc.</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio Pediatrics, Inc.</name>
      <address>
        <city>Huber Heights</city>
        <state>Ohio</state>
        <zip>45424</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio Pediatric Research</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christopher Brad Redden, ARNP Healthcare One Urgent Care and Family Practice</name>
      <address>
        <city>El Reno</city>
        <state>Oklahoma</state>
        <zip>73036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Institute of Norman (LION)</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Health Science Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma State University - Center for Health Sciences - Pediatric Research</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Richard Ohnmacht</name>
      <address>
        <city>Cranston</city>
        <state>Rhode Island</state>
        <zip>02920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Medical Research</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charleston Pediatrics</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Charleson</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Medicine &amp; Pediatric Associates of Bristol, PC</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Bristol</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates, Inc.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tekton Research, Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advances in Health Research, Inc</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Houston Clinical Research Service</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Healthcare of Northwest Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Healthcare of Northwest Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Center for Drug Development, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Child Care Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Steps Pediatrics</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78254</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Healthcare of Northwest Houston, PA</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Healthcare of Northwest Houston</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J. Lewis Resarch Incorporated, Foothill Family Clinic</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research Inc. - Foothill Family Clinic South</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research, Inc. - Jordan River Family Medicine</name>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PI-Coor Clinical Research, LLC</name>
      <address>
        <city>Burke</city>
        <state>Virginia</state>
        <zip>22015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Associates of Charlottesville, PLC</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Associates of Charlottesville, PLC - West Satellite</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Associates of Charlottesville, PLC - North Satellite</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Vancouver Clinic</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98664</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Vancouver Clinic</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98686</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gundersen Clinic, LTD</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monroe Clinic</name>
      <address>
        <city>Monroe</city>
        <state>Wisconsin</state>
        <zip>53566</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1971015&amp;StudyName=A%20Clinical%20Trial%20to%20Study%20the%20Safety%2C%20Tolerance%20and%20Immunogenic%20Response%20to%20MCV4%2C%20Tdap%20and%20bivalent%20rLP2086%20Vaccine%20When%20Given%20at</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2011</study_first_submitted>
  <study_first_submitted_qc>October 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2011</study_first_posted>
  <results_first_submitted>May 7, 2015</results_first_submitted>
  <results_first_submitted_qc>May 7, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 25, 2015</results_first_posted>
  <last_update_submitted>May 7, 2015</last_update_submitted>
  <last_update_submitted_qc>May 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaccine</keyword>
  <keyword>rLP2086</keyword>
  <keyword>MCV4</keyword>
  <keyword>Tdap</keyword>
  <keyword>meningitis B</keyword>
  <keyword>N. meningitidis serogroup B</keyword>
  <keyword>adolescents</keyword>
  <keyword>observer-blind</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 2648 participants were enrolled in this study. Of these, 19 participants were randomized but did not receive study vaccination.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MCV4+Tdap+rLP2086</title>
          <description>Randomized to receive Quadrivalent meningococcal polysaccharide conjugate (MCV4) and Tetanus, diphtheria, and acellular pertussis (Tdap) vaccine on 0- month, Neisseria meningitidis serogroup B (MnB) bivalent recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
        </group>
        <group group_id="P2">
          <title>MCV4+Tdap+Saline</title>
          <description>Randomized to receive MCV4 and Tdap vaccine on 0- month, Saline on a 0-, 2-, 6- month schedule.</description>
        </group>
        <group group_id="P3">
          <title>Saline+Saline+rLP2086</title>
          <description>Randomized to receive Saline on 0- month, rLP2086 vaccine on a 0-, 2-, 6- month schedule, MCV4 and Tdap vaccine on 7- month.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="888"/>
                <participants group_id="P2" count="878"/>
                <participants group_id="P3" count="882"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 1</title>
              <participants_list>
                <participants group_id="P1" count="884"/>
                <participants group_id="P2" count="870"/>
                <participants group_id="P3" count="875"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 2</title>
              <participants_list>
                <participants group_id="P1" count="802"/>
                <participants group_id="P2" count="819"/>
                <participants group_id="P3" count="799"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccination 3</title>
              <participants_list>
                <participants group_id="P1" count="757"/>
                <participants group_id="P2" count="777"/>
                <participants group_id="P3" count="748"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="722"/>
                <participants group_id="P2" count="733"/>
                <participants group_id="P3" count="717"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="166"/>
                <participants group_id="P2" count="145"/>
                <participants group_id="P3" count="165"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Medication error</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No longer meets eligibility criteria</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="51"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No longer willing to participate</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="54"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but not vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat (ITT) population included all participants who were randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>MCV4+Tdap+rLP2086</title>
          <description>Randomized to receive Quadrivalent meningococcal polysaccharide conjugate (MCV4) and Tetanus, diphtheria, and acellular pertussis (Tdap) vaccine on 0- month, Neisseria meningitidis serogroup B (MnB) bivalent recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
        </group>
        <group group_id="B2">
          <title>MCV4+Tdap+Saline</title>
          <description>Randomized to receive MCV4 and Tdap vaccine on 0- month, Saline on a 0-, 2-, 6- month schedule.</description>
        </group>
        <group group_id="B3">
          <title>Saline+Saline+rLP2086</title>
          <description>Randomized to receive Saline on 0- month, rLP2086 vaccine on a 0-, 2-, 6- month schedule, MCV4 and Tdap vaccine on 7- month.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="888"/>
            <count group_id="B2" value="878"/>
            <count group_id="B3" value="882"/>
            <count group_id="B4" value="2648"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.6" spread="0.70"/>
                    <measurement group_id="B2" value="10.6" spread="0.69"/>
                    <measurement group_id="B3" value="10.6" spread="0.67"/>
                    <measurement group_id="B4" value="10.6" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="454"/>
                    <measurement group_id="B2" value="427"/>
                    <measurement group_id="B3" value="417"/>
                    <measurement group_id="B4" value="1298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="434"/>
                    <measurement group_id="B2" value="451"/>
                    <measurement group_id="B3" value="465"/>
                    <measurement group_id="B4" value="1350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentrations (GMC) for Diphtheria and Tetanus Antigens</title>
        <description>Antibody GMCs of 2 antigens of diphtheria and tetanus toxoid were computed in International Units per milliliter (IU/mL) along with corresponding 2-sided 95 percent (%) confidence intervals (CIs). Here, â€˜number of participants analyzedâ€™ signifies participants with valid and determinate assay results for given antigen.</description>
        <time_frame>1 Month after Vaccination 1</time_frame>
        <population>Post vaccination 1 evaluable immunogenicity population: eligible participants randomized to Group 1 or 2, received scheduled investigational product, had pre and post vaccination blood drawn at pre-specified time points, had valid, determinate assay results for proposed analysis, received no prohibited vaccines, no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>MCV4+Tdap+rLP2086</title>
            <description>Randomized to receive Quadrivalent meningococcal polysaccharide conjugate (MCV4) and Tetanus, diphtheria, and acellular pertussis (Tdap) vaccine on 0- month, Neisseria meningitidis serogroup B (MnB) bivalent recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>MCV4+Tdap+Saline</title>
            <description>Randomized to receive MCV4 and Tdap vaccine on 0- month, Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations (GMC) for Diphtheria and Tetanus Antigens</title>
          <description>Antibody GMCs of 2 antigens of diphtheria and tetanus toxoid were computed in International Units per milliliter (IU/mL) along with corresponding 2-sided 95 percent (%) confidence intervals (CIs). Here, â€˜number of participants analyzedâ€™ signifies participants with valid and determinate assay results for given antigen.</description>
          <population>Post vaccination 1 evaluable immunogenicity population: eligible participants randomized to Group 1 or 2, received scheduled investigational product, had pre and post vaccination blood drawn at pre-specified time points, had valid, determinate assay results for proposed analysis, received no prohibited vaccines, no other major protocol violations.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="778"/>
                <count group_id="O2" value="780"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diphtheria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" lower_limit="8.67" upper_limit="9.92"/>
                    <measurement group_id="O2" value="9.8" lower_limit="9.23" upper_limit="10.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" lower_limit="8.95" upper_limit="9.98"/>
                    <measurement group_id="O2" value="10.3" lower_limit="9.75" upper_limit="10.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Diphtheria: CIs for GMC ratio were back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures (Group 1 - Group 2 for Diphtheria antigens).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority criteria margin was 1.5-fold and statistical inference was based on the CIs of the GMC ratios. Non-inferiority was achieved when the lower limit of the 2-sided 95% CI for the GMC ratios after vaccination 1 was greater than 0.67.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tetanus: CIs for GMC ratio were back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures (Group 1 - Group 2 for Tetanus antigens).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority criteria margin was 1.5-fold and statistical inference was based on the CIs of the GMC ratios. Non-inferiority was achieved when the lower limit of the 2-sided 95% CI for the GMC ratios after vaccination 1 was greater than 0.67.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentrations (GMC) for Acellular Pertussis Antigens</title>
        <description>Antibody GMCs of 4 acellular pertussis antigens (pertussis toxoid, pertussis filamentous hemagglutinin, pertussis pertactin and pertussis fimbrial agglutinogens types 2+3) were computed in Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EU/mL) along with corresponding 2-sided 95% CIs.</description>
        <time_frame>1 Month after Vaccination 1</time_frame>
        <population>Post vaccination 1 evaluable immunogenicity population. Here, â€˜number of participants analyzedâ€™ signifies participants with valid and determinate assay results for given antigen.</population>
        <group_list>
          <group group_id="O1">
            <title>MCV4+Tdap+rLP2086</title>
            <description>Randomized to receive Quadrivalent meningococcal polysaccharide conjugate (MCV4) and Tetanus, diphtheria, and acellular pertussis (Tdap) vaccine on 0- month, Neisseria meningitidis serogroup B (MnB) bivalent recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>MCV4+Tdap+Saline</title>
            <description>Randomized to receive MCV4 and Tdap vaccine on 0- month, Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations (GMC) for Acellular Pertussis Antigens</title>
          <description>Antibody GMCs of 4 acellular pertussis antigens (pertussis toxoid, pertussis filamentous hemagglutinin, pertussis pertactin and pertussis fimbrial agglutinogens types 2+3) were computed in Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EU/mL) along with corresponding 2-sided 95% CIs.</description>
          <population>Post vaccination 1 evaluable immunogenicity population. Here, â€˜number of participants analyzedâ€™ signifies participants with valid and determinate assay results for given antigen.</population>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="778"/>
                <count group_id="O2" value="780"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pertussis toxoid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" lower_limit="12.35" upper_limit="14.14"/>
                    <measurement group_id="O2" value="14.2" lower_limit="13.28" upper_limit="15.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis filamentous hemagglutinin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.0" lower_limit="106.15" upper_limit="118.14"/>
                    <measurement group_id="O2" value="122.9" lower_limit="116.42" upper_limit="129.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis pertactin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202.0" lower_limit="187.77" upper_limit="217.25"/>
                    <measurement group_id="O2" value="228.9" lower_limit="212.72" upper_limit="246.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis fimbrial agglutinogens types 2+3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.1" lower_limit="121.20" upper_limit="157.33"/>
                    <measurement group_id="O2" value="154.2" lower_limit="135.30" upper_limit="175.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pertussis toxoid: CIs for GMC ratio were back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures (Group 1 - Group 2 for Pertussis toxoid).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority criteria margin was 1.5-fold and statistical inference was based on the CIs of the GMC ratios. Non-inferiority was achieved when the lower limit of the 2-sided 95% CI for the GMC ratios after vaccination 1 was greater than 0.67.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pertussis filamentous hemagglutinin: CIs for GMC ratio were back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures (Group 1 - Group 2 for pertussis filamentous hemagglutinin antigens).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority criteria margin was 1.5-fold and statistical inference was based on the CIs of the GMC ratios. Non-inferiority was achieved when the lower limit of the 2-sided 95% CI for the GMC ratios after vaccination 1 was greater than 0.67.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pertussis pertactin: CIs for GMC ratio were back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures (Group 1 - Group 2 for pertussis pertactin antigens).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority criteria margin was 1.5-fold and statistical inference was based on the CIs of the GMC ratios. Non-inferiority was achieved when the lower limit of the 2-sided 95% CI for the GMC ratios after vaccination 1 was greater than 0.67.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pertussis fimbriae agglutinogens types 2 + 3: CIs for GMC ratio were back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures (Group 1 - Group 2 for pertussis fimbriae agglutinogens types 2 + 3 antigens).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority criteria margin was 1.5-fold and statistical inference was based on the CIs of the GMC ratios. Non-inferiority was achieved when the lower limit of the 2-sided 95% CI for the GMC ratios after vaccination 1 was greater than 0.67.</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer (GMT) for Meningococcal Conjugate Vaccine (MCV4) Antigens</title>
        <description>Antibody GMTs of 4 MCV4 antigens (serogroup A, serogroup C, serogroup Y and serogroup W-135) were computed along with corresponding 2-sided 95% CIs.</description>
        <time_frame>1 Month after Vaccination 1</time_frame>
        <population>Post vaccination 1 evaluable immunogenicity population. Here, â€˜Nâ€™ signifies participants with valid and determinate assay results for given strain for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>MCV4+Tdap+rLP2086</title>
            <description>Randomized to receive Quadrivalent meningococcal polysaccharide conjugate (MCV4) and Tetanus, diphtheria, and acellular pertussis (Tdap) vaccine on 0- month, Neisseria meningitidis serogroup B (MnB) bivalent recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>MCV4+Tdap+Saline</title>
            <description>Randomized to receive MCV4 and Tdap vaccine on 0- month, Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) for Meningococcal Conjugate Vaccine (MCV4) Antigens</title>
          <description>Antibody GMTs of 4 MCV4 antigens (serogroup A, serogroup C, serogroup Y and serogroup W-135) were computed along with corresponding 2-sided 95% CIs.</description>
          <population>Post vaccination 1 evaluable immunogenicity population. Here, â€˜Nâ€™ signifies participants with valid and determinate assay results for given strain for each group, respectively.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="779"/>
                <count group_id="O2" value="781"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A (N=763, 772)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4647.3" lower_limit="4317.66" upper_limit="5002.09"/>
                    <measurement group_id="O2" value="5113.0" lower_limit="4748.73" upper_limit="5505.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (N=768, 767)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1679.2" lower_limit="1539.63" upper_limit="1831.38"/>
                    <measurement group_id="O2" value="1650.2" lower_limit="1519.01" upper_limit="1792.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (N=771, 770)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2212.6" lower_limit="2056.08" upper_limit="2381.08"/>
                    <measurement group_id="O2" value="2244.9" lower_limit="2088.70" upper_limit="2412.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135 (N=751, 765)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5925.1" lower_limit="5469.77" upper_limit="6418.33"/>
                    <measurement group_id="O2" value="6367.9" lower_limit="5872.68" upper_limit="6904.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serogroup A: CIs for GMT ratio were back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures (Group 1 - Group 2 for Serogroup A antigens).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority criteria margin was 1.5-fold and statistical inference was based on the CIs of the GMT ratios. Non-inferiority was achieved when the lower limit of the 2-sided 95% CI for the GMT ratios after vaccination 1 was greater than 0.67</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serogroup C: CIs for GMT ratio were back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures (Group 1 - Group 2 for Serogroup C antigens).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority criteria margin was 1.5-fold and statistical inference was based on the CIs of the GMT ratios. Non-inferiority was achieved when the lower limit of the 2-sided 95% CI for the GMT ratios after vaccination 1 was greater than 0.67.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serogroup Y: CIs for GMT ratio were back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures (Group 1 - Group 2 for Serogroup Y antigens).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority criteria margin was 1.5-fold and statistical inference was based on the CIs of the GMT ratios. Non-inferiority was achieved when the lower limit of the 2-sided 95% CI for the GMT ratios after vaccination 1 was greater than 0.67.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Serogroup W-135: CIs for GMT ratio were back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures (Group 1 - Group 2 for Serogroup W-135 antigens).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority criteria margin was 1.5-fold and statistical inference was based on the CIs of the GMT ratios. Non-inferiority was achieved when the lower limit of the 2-sided 95% CI for the GMT ratios after vaccination 1 was greater than 0.67.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Bactericidal Assay Using Human Complement (hSBA) GMTs of PMB80 [A22] and PMB2948 [B24] 1 Month After Vaccination 3</title>
        <description>Antibody hSBA GMTs of primary strain PMB80 [A22] and PMB2948 [B24] were computed along with corresponding 2-sided 95% CIs. hSBA titers from the 2 primary strains were logarithmically transformed for analysis. Here, â€˜number of participants analyzedâ€™ signifies evaluable immunogenicity population and 'N' signifies participants with valid and determinate assay results for given strain for each group, respectively.</description>
        <time_frame>1 Month after Vaccination 3</time_frame>
        <population>Post vaccination 3 evaluable immunogenicity population: eligible participants randomized to Group 1 or 3, received scheduled investigational product, had pre and post vaccination blood drawn at pre-specified time points, had valid, determinate assay results for proposed analysis, received no prohibited vaccines, no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>MCV4+Tdap+rLP2086</title>
            <description>Randomized to receive Quadrivalent meningococcal polysaccharide conjugate (MCV4) and Tetanus, diphtheria, and acellular pertussis (Tdap) vaccine on 0- month, Neisseria meningitidis serogroup B (MnB) bivalent recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Saline+Saline+rLP2086</title>
            <description>Randomized to receive Saline on 0- month, rLP2086 vaccine on a 0-, 2-, 6- month schedule, MCV4 and Tdap vaccine on 7- month.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Bactericidal Assay Using Human Complement (hSBA) GMTs of PMB80 [A22] and PMB2948 [B24] 1 Month After Vaccination 3</title>
          <description>Antibody hSBA GMTs of primary strain PMB80 [A22] and PMB2948 [B24] were computed along with corresponding 2-sided 95% CIs. hSBA titers from the 2 primary strains were logarithmically transformed for analysis. Here, â€˜number of participants analyzedâ€™ signifies evaluable immunogenicity population and 'N' signifies participants with valid and determinate assay results for given strain for each group, respectively.</description>
          <population>Post vaccination 3 evaluable immunogenicity population: eligible participants randomized to Group 1 or 3, received scheduled investigational product, had pre and post vaccination blood drawn at pre-specified time points, had valid, determinate assay results for proposed analysis, received no prohibited vaccines, no other major protocol violations.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="683"/>
                <count group_id="O2" value="679"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PMB80 [A22] (N=679, 674)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.9" lower_limit="42.74" upper_limit="49.35"/>
                    <measurement group_id="O2" value="49.7" lower_limit="46.43" upper_limit="53.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2948 [B24] (N=670, 656)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8" lower_limit="23.11" upper_limit="26.58"/>
                    <measurement group_id="O2" value="27.4" lower_limit="25.58" upper_limit="29.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PMB80 [A22]: CIs for GMT ratio were back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures (Group 1 - Group 2 for hSBA strain titers).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority criteria margin was 1.5-fold and statistical inference was based on the CIs of the GMT ratios. Non-inferiority was achieved when the lower limit of the 2-sided 95% CI for the GMT ratios after vaccination 1 was greater than 0.67.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PMB2948 [B24]: CIs for GMT ratio were back transformations of a confidence interval based on the Student t distribution for the mean difference of the logarithms of the measures (Group 1 - Group 2 for hSBA strain titers).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority criteria margin was 1.5-fold and statistical inference was based on the CIs of the GMT ratios. Non-inferiority was achieved when the lower limit of the 2-sided 95% CI for the GMT ratios after vaccination 1 was greater than 0.67.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroresponse for Tetanus, Diphtheria and Acellular Pertussis (Tdap) and Meningococcal Conjugate Vaccine (MCV4) Antigens</title>
        <description>Seroconversion rate for Tdap antigens was defined as greater than or equal to (&gt;=) 4-, 2-fold rise in antibody concentration, if prevaccination antibody concentration was less than or equal to (&lt;=), greater than (&gt;) cutoff value, respectively. For MCV4 antigens &gt;=4-fold rise on serum bactericidal assay using rabbit complement (rSBA) titers if baseline value &gt;= lower limit of quantitation (LLOQ), postdose rSBA titers &gt;=2Ã—LLOQ if baseline value was less than (&lt;) LLOQ. Cutoff value =0.1 IU/mL for diphtheria and tetanus, 0.9,2.9,3.0,10.6 EU/mL for pertussis toxoid, filamentous hemagglutinin, pertactin, fimbriae agglutinogens types 2 + 3, respectively.</description>
        <time_frame>1 Month after Vaccination 1</time_frame>
        <population>Post vaccination 1 evaluable immunogenicity population. Here, â€˜number of participants analyzedâ€™ signifies participants with valid, determinate assay results for given antigen at specified time point and baseline. 'N' signifies number of participants with seroresponse.</population>
        <group_list>
          <group group_id="O1">
            <title>MCV4+Tdap+rLP2086</title>
            <description>Randomized to receive Quadrivalent meningococcal polysaccharide conjugate (MCV4) and Tetanus, diphtheria, and acellular pertussis (Tdap) vaccine on 0- month, Neisseria meningitidis serogroup B (MnB) bivalent recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>MCV4+Tdap+Saline</title>
            <description>Randomized to receive MCV4 and Tdap vaccine on 0- month, Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroresponse for Tetanus, Diphtheria and Acellular Pertussis (Tdap) and Meningococcal Conjugate Vaccine (MCV4) Antigens</title>
          <description>Seroconversion rate for Tdap antigens was defined as greater than or equal to (&gt;=) 4-, 2-fold rise in antibody concentration, if prevaccination antibody concentration was less than or equal to (&lt;=), greater than (&gt;) cutoff value, respectively. For MCV4 antigens &gt;=4-fold rise on serum bactericidal assay using rabbit complement (rSBA) titers if baseline value &gt;= lower limit of quantitation (LLOQ), postdose rSBA titers &gt;=2Ã—LLOQ if baseline value was less than (&lt;) LLOQ. Cutoff value =0.1 IU/mL for diphtheria and tetanus, 0.9,2.9,3.0,10.6 EU/mL for pertussis toxoid, filamentous hemagglutinin, pertactin, fimbriae agglutinogens types 2 + 3, respectively.</description>
          <population>Post vaccination 1 evaluable immunogenicity population. Here, â€˜number of participants analyzedâ€™ signifies participants with valid, determinate assay results for given antigen at specified time point and baseline. 'N' signifies number of participants with seroresponse.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="779"/>
                <count group_id="O2" value="781"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diphtheria (N=774, 780)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.6" lower_limit="97.5" upper_limit="99.3"/>
                    <measurement group_id="O2" value="98.3" lower_limit="97.2" upper_limit="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus (N=774, 780)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7" lower_limit="96.3" upper_limit="98.6"/>
                    <measurement group_id="O2" value="97.4" lower_limit="96.1" upper_limit="98.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis toxoid (N=774, 780)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.1" lower_limit="64.7" upper_limit="71.4"/>
                    <measurement group_id="O2" value="72.7" lower_limit="69.4" upper_limit="75.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis filamentous hemagglutinin (N=774, 780)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.3" lower_limit="82.6" upper_limit="87.7"/>
                    <measurement group_id="O2" value="89.2" lower_limit="86.8" upper_limit="91.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis pertactin (N=774, 780)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0" lower_limit="94.4" upper_limit="97.3"/>
                    <measurement group_id="O2" value="96.2" lower_limit="94.6" upper_limit="97.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis fimbriae AG types 2+3 (N=774, 780)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.5" lower_limit="76.4" upper_limit="82.3"/>
                    <measurement group_id="O2" value="81.9" lower_limit="79.0" upper_limit="84.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A (N=712, 736)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.4" lower_limit="82.6" upper_limit="87.9"/>
                    <measurement group_id="O2" value="88.6" lower_limit="86.1" upper_limit="90.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (N=738, 742)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.3" lower_limit="86.8" upper_limit="91.4"/>
                    <measurement group_id="O2" value="88.9" lower_limit="86.5" upper_limit="91.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (N=754, 753)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.5" lower_limit="88.1" upper_limit="92.5"/>
                    <measurement group_id="O2" value="93.6" lower_limit="91.6" upper_limit="95.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W-135 (N=729, 752)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.1" lower_limit="95.6" upper_limit="98.2"/>
                    <measurement group_id="O2" value="97.2" lower_limit="95.8" upper_limit="98.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Predefined Antibody Level for Diphtheria and Tetanus Antigens</title>
        <description>Participants with antibody concentration level of greater than or equal to 1.0 IU/mL for diphtheria and tetanus antigens were computed along with corresponding 2-sided 95% CIs.</description>
        <time_frame>1 Month after Vaccination 1</time_frame>
        <population>Post vaccination 1 evaluable immunogenicity population. Here, â€˜number of participants analyzedâ€™ signifies participants with valid, determinate assay results for given antigen.</population>
        <group_list>
          <group group_id="O1">
            <title>MCV4+Tdap+rLP2086</title>
            <description>Randomized to receive Quadrivalent meningococcal polysaccharide conjugate (MCV4) and Tetanus, diphtheria, and acellular pertussis (Tdap) vaccine on 0- month, Neisseria meningitidis serogroup B (MnB) bivalent recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>MCV4+Tdap+Saline</title>
            <description>Randomized to receive MCV4 and Tdap vaccine on 0- month, Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Predefined Antibody Level for Diphtheria and Tetanus Antigens</title>
          <description>Participants with antibody concentration level of greater than or equal to 1.0 IU/mL for diphtheria and tetanus antigens were computed along with corresponding 2-sided 95% CIs.</description>
          <population>Post vaccination 1 evaluable immunogenicity population. Here, â€˜number of participants analyzedâ€™ signifies participants with valid, determinate assay results for given antigen.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="778"/>
                <count group_id="O2" value="780"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tetanus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.1" lower_limit="98.2" upper_limit="99.6"/>
                    <measurement group_id="O2" value="99.0" lower_limit="98.0" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diphtheria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.1" lower_limit="96.8" upper_limit="98.9"/>
                    <measurement group_id="O2" value="99.0" lower_limit="98.0" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Bactericidal Assay Using Human Complement (hSBA) GMTs of PMB80 [A22] and PMB2948 [B24] Before Vaccination 1 and 1 Month After Vaccination 2</title>
        <description>Antibody hSBA of primary strain PMB80 [A22] and PMB2948 [B24] were computed along with corresponding 2-sided 95% CIs. hSBA titers from the 2 primary strains were logarithmically transformed for analysis.</description>
        <time_frame>Before Vaccination 1, 1 Month after Vaccination (Vac) 2</time_frame>
        <population>Post vaccination 3 evaluable immunogenicity population. Here, â€˜number of participants analyzedâ€™ signifies evaluable immunogenicity population and 'N' signifies participants with valid and determinate assay results for given strain for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>MCV4+Tdap+rLP2086</title>
            <description>Randomized to receive Quadrivalent meningococcal polysaccharide conjugate (MCV4) and Tetanus, diphtheria, and acellular pertussis (Tdap) vaccine on 0- month, Neisseria meningitidis serogroup B (MnB) bivalent recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Saline+Saline+rLP2086</title>
            <description>Randomized to receive Saline on 0- month, rLP2086 vaccine on a 0-, 2-, 6- month schedule, MCV4 and Tdap vaccine on 7- month.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Bactericidal Assay Using Human Complement (hSBA) GMTs of PMB80 [A22] and PMB2948 [B24] Before Vaccination 1 and 1 Month After Vaccination 2</title>
          <description>Antibody hSBA of primary strain PMB80 [A22] and PMB2948 [B24] were computed along with corresponding 2-sided 95% CIs. hSBA titers from the 2 primary strains were logarithmically transformed for analysis.</description>
          <population>Post vaccination 3 evaluable immunogenicity population. Here, â€˜number of participants analyzedâ€™ signifies evaluable immunogenicity population and 'N' signifies participants with valid and determinate assay results for given strain for each group, respectively.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="683"/>
                <count group_id="O2" value="679"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Vaccination 1: PMB80 [A22] (N=677, 677)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="8.28" upper_limit="8.64"/>
                    <measurement group_id="O2" value="8.6" lower_limit="8.39" upper_limit="8.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB2948 [B24] (N=677, 676)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="4.04" upper_limit="4.19"/>
                    <measurement group_id="O2" value="4.2" lower_limit="4.10" upper_limit="4.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Month after Vac 2: PMB80 [A22] (N=669, 665)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.7" lower_limit="22.10" upper_limit="25.40"/>
                    <measurement group_id="O2" value="23.8" lower_limit="22.14" upper_limit="25.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Month after Vac 2: PMB2948 [B24] (N=656, 650)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" lower_limit="11.12" upper_limit="12.99"/>
                    <measurement group_id="O2" value="13.0" lower_limit="12.03" upper_limit="14.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer &gt;= Lower Limit of Quantitation (LLOQ)</title>
        <description>Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95% CIs. LLOQ was 1:16 for PMB80 [A22] and 1:8 for PMB2948 [B24].</description>
        <time_frame>Before Vaccination 1, 1 Month after Vaccination (Vac) 2, 3</time_frame>
        <population>Post vaccination 3 evaluable immunogenicity population. Here, â€˜number of participants analyzedâ€™ signifies evaluable immunogenicity population and 'N' signifies participants with valid and determinate assay results for given strain for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>MCV4+Tdap+rLP2086</title>
            <description>Randomized to receive Quadrivalent meningococcal polysaccharide conjugate (MCV4) and Tetanus, diphtheria, and acellular pertussis (Tdap) vaccine on 0- month, Neisseria meningitidis serogroup B (MnB) bivalent recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Saline+Saline+rLP2086</title>
            <description>Randomized to receive Saline on 0- month, rLP2086 vaccine on a 0-, 2-, 6- month schedule, MCV4 and Tdap vaccine on 7- month.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer &gt;= Lower Limit of Quantitation (LLOQ)</title>
          <description>Percentage of participants achieving hSBA titer &gt;= LLOQ were computed along with corresponding 2-sided 95% CIs. LLOQ was 1:16 for PMB80 [A22] and 1:8 for PMB2948 [B24].</description>
          <population>Post vaccination 3 evaluable immunogenicity population. Here, â€˜number of participants analyzedâ€™ signifies evaluable immunogenicity population and 'N' signifies participants with valid and determinate assay results for given strain for each group, respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="683"/>
                <count group_id="O2" value="679"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Vaccination 1: PMB80[A22] 1:16 (N=677, 677)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="3.0" upper_limit="6.3"/>
                    <measurement group_id="O2" value="5.6" lower_limit="4.0" upper_limit="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB80[A22] 1:16 (N= 669, 665)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.0" lower_limit="64.3" upper_limit="71.5"/>
                    <measurement group_id="O2" value="68.0" lower_limit="64.3" upper_limit="71.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB80 [A22] 1:16 (N=679, 674)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5" lower_limit="84.8" upper_limit="89.9"/>
                    <measurement group_id="O2" value="91.4" lower_limit="89.0" upper_limit="93.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB2948[B24] 1:8 (N=677,676)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="0.8" upper_limit="2.9"/>
                    <measurement group_id="O2" value="3.4" lower_limit="2.2" upper_limit="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2948[B24] 1:8 (N=656, 650)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.3" lower_limit="58.5" upper_limit="66.1"/>
                    <measurement group_id="O2" value="66.0" lower_limit="62.2" upper_limit="69.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2948[B24] 1:8 (N=670, 656)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0" lower_limit="87.5" upper_limit="92.2"/>
                    <measurement group_id="O2" value="92.7" lower_limit="90.4" upper_limit="94.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer &gt;= Prespecified Titer Level</title>
        <description>Antibody hSBA of primary strain PMB80 [A22] and PMB2948 [B24] with hSBA titers &gt;=1:4, &gt;=1:8, &gt;=1:16, &gt;=1:32, &gt;=1:64, and &gt;=1:128 were computed along with corresponding 2-sided 95% CIs.</description>
        <time_frame>Before Vaccination 1, 1 Month after Vaccination (Vac) 2, 3</time_frame>
        <population>Post vaccination 3 evaluable immunogenicity population. Here, â€˜number of participants analyzedâ€™ signifies evaluable immunogenicity population and 'N' signifies participants with valid and determinate assay results for given strain for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>MCV4+Tdap+rLP2086</title>
            <description>Randomized to receive Quadrivalent meningococcal polysaccharide conjugate (MCV4) and Tetanus, diphtheria, and acellular pertussis (Tdap) vaccine on 0- month, Neisseria meningitidis serogroup B (MnB) bivalent recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Saline+Saline+rLP2086</title>
            <description>Randomized to receive Saline on 0- month, rLP2086 vaccine on a 0-, 2-, 6- month schedule, MCV4 and Tdap vaccine on 7- month.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer &gt;= Prespecified Titer Level</title>
          <description>Antibody hSBA of primary strain PMB80 [A22] and PMB2948 [B24] with hSBA titers &gt;=1:4, &gt;=1:8, &gt;=1:16, &gt;=1:32, &gt;=1:64, and &gt;=1:128 were computed along with corresponding 2-sided 95% CIs.</description>
          <population>Post vaccination 3 evaluable immunogenicity population. Here, â€˜number of participants analyzedâ€™ signifies evaluable immunogenicity population and 'N' signifies participants with valid and determinate assay results for given strain for each group, respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="683"/>
                <count group_id="O2" value="679"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Vaccination 1: PMB80[A22] 1:4 (N=677,677)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" lower_limit="5.1" upper_limit="9.1"/>
                    <measurement group_id="O2" value="7.5" lower_limit="5.7" upper_limit="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB80[A22] 1:4 (N=669, 665)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.2" lower_limit="64.5" upper_limit="71.7"/>
                    <measurement group_id="O2" value="68.6" lower_limit="64.9" upper_limit="72.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB80[A22] 1:4 (N=679, 674)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.8" lower_limit="85.1" upper_limit="90.1"/>
                    <measurement group_id="O2" value="91.7" lower_limit="89.3" upper_limit="93.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB80[A22] 1:8 (N=677, 677)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="3.5" upper_limit="6.9"/>
                    <measurement group_id="O2" value="6.4" lower_limit="4.6" upper_limit="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB80[A22] 1:8 (N=669, 665)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.2" lower_limit="64.5" upper_limit="71.7"/>
                    <measurement group_id="O2" value="68.1" lower_limit="64.4" upper_limit="71.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB80[A22] 1:8 (N=679, 674)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.6" lower_limit="84.9" upper_limit="90.0"/>
                    <measurement group_id="O2" value="91.5" lower_limit="89.2" upper_limit="93.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB80[A22] 1:32 (N=677, 677)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="1.6" upper_limit="4.2"/>
                    <measurement group_id="O2" value="3.2" lower_limit="2.0" upper_limit="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB80[A22] 1:32 (N=669, 665)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.0" lower_limit="51.1" upper_limit="58.8"/>
                    <measurement group_id="O2" value="54.4" lower_limit="50.6" upper_limit="58.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB80[A22] 1:32 (N=679, 674)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.3" lower_limit="78.2" upper_limit="84.2"/>
                    <measurement group_id="O2" value="84.7" lower_limit="81.8" upper_limit="87.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB80[A22] 1:64 (N=677,677)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="0.2" upper_limit="1.7"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.4" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB80[A22] 1:64 (N= 669, 665)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6" lower_limit="22.3" upper_limit="29.0"/>
                    <measurement group_id="O2" value="25.0" lower_limit="21.7" upper_limit="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB80[A22] 1:64 (N=679, 674)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.7" lower_limit="48.9" upper_limit="56.5"/>
                    <measurement group_id="O2" value="55.6" lower_limit="51.8" upper_limit="59.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB80[A22] 1:128 (N=677,677)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0.0" upper_limit="0.8"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.1" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB80[A22] 1:128 (N=669, 665)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" lower_limit="5.1" upper_limit="9.1"/>
                    <measurement group_id="O2" value="7.5" lower_limit="5.6" upper_limit="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB80[A22] 1:128 (N=679, 674)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.6" lower_limit="20.4" upper_limit="26.9"/>
                    <measurement group_id="O2" value="23.3" lower_limit="20.2" upper_limit="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB2948[B24] 1:4 (N=677,676)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1.1" upper_limit="3.4"/>
                    <measurement group_id="O2" value="3.7" lower_limit="2.4" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2948[B24] 1:4 (N=656, 650)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.8" lower_limit="61.0" upper_limit="68.4"/>
                    <measurement group_id="O2" value="68.2" lower_limit="64.4" upper_limit="71.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2948[B24] 1:4 (N=670, 656)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.7" lower_limit="88.3" upper_limit="92.8"/>
                    <measurement group_id="O2" value="93.1" lower_limit="90.9" upper_limit="95.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB2948[B24] 1:16(N=677,676)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0.7" upper_limit="2.7"/>
                    <measurement group_id="O2" value="2.1" lower_limit="1.1" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2948[B24] 1:16(N=656,650)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.6" lower_limit="53.7" upper_limit="61.4"/>
                    <measurement group_id="O2" value="60.3" lower_limit="56.4" upper_limit="64.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2948[B24] 1:16(N=670,656)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.7" lower_limit="83.9" upper_limit="89.2"/>
                    <measurement group_id="O2" value="88.9" lower_limit="86.2" upper_limit="91.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: PMB2948[B24] 1:32(N=677,676)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.1" upper_limit="1.3"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.2" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2948[B24] 1:32(N=656,650)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2" lower_limit="22.9" upper_limit="29.8"/>
                    <measurement group_id="O2" value="28.2" lower_limit="24.7" upper_limit="31.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2948[B24] 1:32(N=670, 656)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.1" lower_limit="51.2" upper_limit="58.9"/>
                    <measurement group_id="O2" value="60.7" lower_limit="56.8" upper_limit="64.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1:PMB2948[B24] 1:64(N= 677,676)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.1" upper_limit="1.3"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.0" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2948[B24] 1:64 (N=656,650)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" lower_limit="6.6" upper_limit="11.1"/>
                    <measurement group_id="O2" value="10.3" lower_limit="8.1" upper_limit="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2948[B24] 1:64 (N=670,656)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" lower_limit="19.4" upper_limit="25.9"/>
                    <measurement group_id="O2" value="24.1" lower_limit="20.9" upper_limit="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1:PMB2948[B24] 1:128(N=677,676)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0.0" upper_limit="0.8"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0.0" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2: PMB2948[B24] 1:128(N=656,650)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="1.4" upper_limit="3.9"/>
                    <measurement group_id="O2" value="3.4" lower_limit="2.1" upper_limit="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3: PMB2948[B24] 1:128(N=670,656)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" lower_limit="4.8" upper_limit="8.7"/>
                    <measurement group_id="O2" value="7.8" lower_limit="5.8" upper_limit="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Immunogloblulin G (IgG) Measured by GMC</title>
        <description>IgG GMCs of 4 MCV4 antigens (serogroup A, serogroup C, serogroup Y and serogroup W-135) of participants were computed along with corresponding 2-sided 95% CIs. CIs were back transformations of confidence levels based on Student t distribution for mean logarithm of titers.</description>
        <time_frame>Before Vaccination 1, 1 Month after Vaccination 1</time_frame>
        <population>Post vaccination 1 evaluable immunogenicity population.</population>
        <group_list>
          <group group_id="O1">
            <title>MCV4+Tdap+rLP2086</title>
            <description>Randomized to receive Quadrivalent meningococcal polysaccharide conjugate (MCV4) and Tetanus, diphtheria, and acellular pertussis (Tdap) vaccine on 0- month, Neisseria meningitidis serogroup B (MnB) bivalent recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>MCV4+Tdap+Saline</title>
            <description>Randomized to receive MCV4 and Tdap vaccine on 0- month, Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogloblulin G (IgG) Measured by GMC</title>
          <description>IgG GMCs of 4 MCV4 antigens (serogroup A, serogroup C, serogroup Y and serogroup W-135) of participants were computed along with corresponding 2-sided 95% CIs. CIs were back transformations of confidence levels based on Student t distribution for mean logarithm of titers.</description>
          <population>Post vaccination 1 evaluable immunogenicity population.</population>
          <units>microgram per milliliter (mcg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="779"/>
                <count group_id="O2" value="781"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before Vaccination 1: Serogroup A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" lower_limit="0.16" upper_limit="0.19"/>
                    <measurement group_id="O2" value="0.15" lower_limit="0.14" upper_limit="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Month after Vaccination 1: Serogroup A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.42" lower_limit="10.30" upper_limit="12.65"/>
                    <measurement group_id="O2" value="11.38" lower_limit="10.21" upper_limit="12.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: Serogroup C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" lower_limit="0.10" upper_limit="0.12"/>
                    <measurement group_id="O2" value="0.11" lower_limit="0.10" upper_limit="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Month after Vaccination 1: Serogroup C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.59" lower_limit="4.90" upper_limit="6.39"/>
                    <measurement group_id="O2" value="5.47" lower_limit="4.79" upper_limit="6.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: Serogroup Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" lower_limit="0.13" upper_limit="0.14"/>
                    <measurement group_id="O2" value="0.13" lower_limit="0.13" upper_limit="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Month after Vaccination 1: Serogroup Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.49" lower_limit="2.22" upper_limit="2.79"/>
                    <measurement group_id="O2" value="2.14" lower_limit="1.92" upper_limit="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Before Vaccination 1: Serogroup W-135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" lower_limit="0.13" upper_limit="0.14"/>
                    <measurement group_id="O2" value="0.13" lower_limit="0.13" upper_limit="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Month after Vaccination 1: Serogroup W-135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.79" lower_limit="1.59" upper_limit="2.01"/>
                    <measurement group_id="O2" value="1.84" lower_limit="1.62" upper_limit="2.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Achieving at Least 4-Fold Increase in Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level</title>
        <time_frame>1 Month after Vaccination (Vac) 2, 3</time_frame>
        <population>Post vaccination 3 evaluable immunogenicity population. Here, â€˜number of participants analyzedâ€™ signifies evaluable immunogenicity population and 'N' signifies participants with valid and determinate hSBA titers for the given strain at both the specified time point and baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>MCV4+Tdap+rLP2086</title>
            <description>Randomized to receive Quadrivalent meningococcal polysaccharide conjugate (MCV4) and Tetanus, diphtheria, and acellular pertussis (Tdap) vaccine on 0- month, Neisseria meningitidis serogroup B (MnB) bivalent recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Saline+Saline+rLP2086</title>
            <description>Randomized to receive Saline on 0- month, rLP2086 vaccine on a 0-, 2-, 6- month schedule, MCV4 and Tdap vaccine on 7- month.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving at Least 4-Fold Increase in Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level</title>
          <population>Post vaccination 3 evaluable immunogenicity population. Here, â€˜number of participants analyzedâ€™ signifies evaluable immunogenicity population and 'N' signifies participants with valid and determinate hSBA titers for the given strain at both the specified time point and baseline.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="683"/>
                <count group_id="O2" value="679"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 month after Vac 2 : PMB80 [A22] (N=663, 663)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.3" lower_limit="60.5" upper_limit="67.9"/>
                    <measurement group_id="O2" value="63.7" lower_limit="59.9" upper_limit="67.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3 : PMB80 [A22] (N=673, 672)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.0" lower_limit="81.0" upper_limit="86.6"/>
                    <measurement group_id="O2" value="88.7" lower_limit="86.0" upper_limit="91.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 2 : PMB2948 [B24] (N=650, 647)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.3" lower_limit="52.4" upper_limit="60.2"/>
                    <measurement group_id="O2" value="58.4" lower_limit="54.5" upper_limit="62.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after Vac 3 : PMB2948 [B24] (N=664, 653)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.7" lower_limit="82.8" upper_limit="88.3"/>
                    <measurement group_id="O2" value="87.7" lower_limit="85.0" upper_limit="90.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With at Least One Adverse Event (AE)</title>
        <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.</description>
        <time_frame>Vaccination phase (baseline up to 1 month after Vaccination 3); Follow-up phase (from 1 month up to 6 months after Vaccination 3)</time_frame>
        <population>Safety population included all participants who received at least 1 dose of the investigational product and had safety information available. 'N' signifies participants evaluable for this measure during specified time period.</population>
        <group_list>
          <group group_id="O1">
            <title>MCV4+Tdap+rLP2086</title>
            <description>Randomized to receive Quadrivalent meningococcal polysaccharide conjugate (MCV4) and Tetanus, diphtheria, and acellular pertussis (Tdap) vaccine on 0- month, Neisseria meningitidis serogroup B (MnB) bivalent recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O2">
            <title>MCV4+Tdap+Saline</title>
            <description>Randomized to receive MCV4 and Tdap vaccine on 0- month, Saline on a 0-, 2-, 6- month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Saline+Saline+rLP2086</title>
            <description>Randomized to receive Saline on 0- month, rLP2086 vaccine on a 0-, 2-, 6- month schedule, MCV4 and Tdap vaccine on 7- month.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least One Adverse Event (AE)</title>
          <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship.</description>
          <population>Safety population included all participants who received at least 1 dose of the investigational product and had safety information available. 'N' signifies participants evaluable for this measure during specified time period.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="883"/>
                <count group_id="O2" value="870"/>
                <count group_id="O3" value="875"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vaccination phase: Adverse Events (N=883,870,875)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9"/>
                    <measurement group_id="O2" value="42.6"/>
                    <measurement group_id="O3" value="46.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up phase: Adverse Events (N=777,776,771)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs: recorded from signing of informed consent form (ICF) to completion of study. SAEs: recorded from signing of ICF to 196 days of follow up period. Participant recorded preÂ­-specified AEs in electronic diary (up to 7 days after vaccination)</time_frame>
      <desc>SAEs and AEs were grouped by system organ class and preferred term. AEs included AEs collected in the electronic diary (local and systemic reactions; systematic assessment) and AEs collected on the case report form at each visit (nonsystematic assessment).</desc>
      <group_list>
        <group group_id="E1">
          <title>MCV4+Tdap+rLP2086</title>
          <description>Randomized to receive Quadrivalent meningococcal polysaccharide conjugate (MCV4) and Tetanus, diphtheria, and acellular pertussis (Tdap) vaccine on 0- month, Neisseria meningitidis serogroup B (MnB) bivalent recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.</description>
        </group>
        <group group_id="E2">
          <title>MCV4+Tdap+Saline</title>
          <description>Randomized to receive MCV4 and Tdap vaccine on 0- month, Saline on a 0-, 2-, 6- month schedule.</description>
        </group>
        <group group_id="E3">
          <title>Saline+Saline+rLP2086</title>
          <description>Randomized to receive Saline on 0- month, rLP2086 vaccine on a 0-, 2-, 6- month schedule, MCV4 and Tdap vaccine on 7- month.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v 17.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="875"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenogenital syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Congenital spinal cord anomaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="875"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="875"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Bone abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="875"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Epiphyseal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Wound secretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="875"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="875"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Scoliosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="875"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Dural arteriovenous fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Hemiplegic migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="875"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Depression suicidal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Encopresis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Post-traumatic stress disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Psychogenic seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="875"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Pneumomediastinum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="875"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="875"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA v 17.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="277" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="260" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="292" subjects_at_risk="875"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="875"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="875"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="70" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="875"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="875"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="875"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="875"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="875"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="875"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="875"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="883"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="870"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="875"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

